专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US06486208B1 Sustained release, and comfortable opthalmic composition and method for ocular therapy 失效
标题翻译：持续释放，舒适的眼用组合物和眼部治疗方法
公开(公告)号：US06486208B1
公开(公告)日：2002-11-26
申请号：US09787203
申请日：2001-03-15
申请人： Ernesto J. Castillo , Ruma Sarkar , Onkar N. Singh , Alan L. Weiner , Cody Yarborough
发明人： Ernesto J. Castillo , Ruma Sarkar , Onkar N. Singh , Alan L. Weiner , Cody Yarborough
IPC分类号： A61K31135
CPC分类号： A61K9/0048 , Y10S514/912
摘要： This invention relates to reduced stinging, sustained release ophthalmic formulations and the method of treatment comprising administering such formulations topically to the eye when in need thereof.
摘要翻译：本发明涉及减少刺痛，持续释放的眼用制剂和治疗方法，包括在有需要时将这些制剂局部施用于眼睛。

12. 发明授权

US06352716B1 Steroidal liposomes 失效
标题翻译：类固醇脂质体
公开(公告)号：US06352716B1
公开(公告)日：2002-03-05
申请号：US08108822
申请日：1993-08-18
申请人： Andrew S. Janoff , Mircea C. Popescu , Alan L. Weiner , Lois E. Bolcsak , Paul A. Tremblay , Christine E. Swenson
发明人： Andrew S. Janoff , Mircea C. Popescu , Alan L. Weiner , Lois E. Bolcsak , Paul A. Tremblay , Christine E. Swenson
IPC分类号： A61K9127
CPC分类号： A61K9/1271 , A61K9/0014 , A61K9/0019 , A61K9/0034 , A61K9/02 , A61K9/12 , A61K9/1272 , A61K47/12 , A61K47/28 , A61K2039/55555 , C12N15/88 , Y10S424/15 , Y10S436/829 , Y10S514/887 , Y10S514/967 , Y10T428/2984
摘要： Methods and compositions are described for the preparation of bioactive agents entrapped in lipid vesicles the bilayers of which comprise a salt form of an organic acid derivative of a sterol, such as the tris-salt form of a sterol hemisuccinate, and to bompositions comprising a mixtue of tris(hydroxymethyl)aminomethane salt of cholesteryl hemisuccinate with either an antifungal compound or a peptide. These compositions have various applications in vivo.
摘要翻译：描述了用于制备包含在脂质囊泡中的生物活性剂的方法和组合物，其双层包含固醇的有机酸衍生物的盐形式，例如半琥珀酸固醇的三盐形式，以及包含混合物胆固醇半琥珀酸盐的三（羟甲基）氨基甲烷盐与抗真菌化合物或肽。这些组合物在体内具有各种应用。

13. 发明授权

US06235781B1 Prostaglandin product 有权
标题翻译：前列腺素产品
公开(公告)号：US06235781B1
公开(公告)日：2001-05-22
申请号：US09487936
申请日：2000-01-20
申请人： Alan L. Weiner , Subhash C. Airy , Cody Yarborough , Julia A. Clifford , William E. McCune
发明人： Alan L. Weiner , Subhash C. Airy , Cody Yarborough , Julia A. Clifford , William E. McCune
IPC分类号： A61K31215
CPC分类号： A61K31/5575 , A61K9/0048 , A61K47/44 , Y10S514/912
摘要： A pharmaceutical product comprising an aqueous prostaglandin formulation and a polypropylene container are disclosed. Aqueous prostaglandin formulations are more stable in polypropylene containers than polyethylene containers.
摘要翻译：公开了包含前列腺素水溶液制剂和聚丙烯容器的药物制品。水性前列腺素制剂在聚丙烯容器中比聚乙烯容器更稳定。

14. 发明授权

US5626873A Emulsions 失效
标题翻译：乳液
公开(公告)号：US5626873A
公开(公告)日：1997-05-06
申请号：US442080
申请日：1995-05-16
申请人： Alan L. Weiner , Sharon Carpenter-Green
发明人： Alan L. Weiner , Sharon Carpenter-Green
IPC分类号： A61K9/00 , A61K47/24 , A61K9/66 , A61K38/00
CPC分类号： A61K9/0026 , A61K47/24 , A61K9/0014 , A61K9/0019 , Y10S514/938 , Y10S514/944 , Y10S514/975
摘要： A novel oil and water emulsion useful for delivery of a bioactive agent is disclosed. The emulsion comprises a first HLB requirement amount of surfactant dioleoyl phosphatidylethanolamine. In particular embodiments the emulsion includes a secondary surfactant other than dioleoyl phosphatidylethanolamine except in the limiting case wherein the HLB requirement is the HLB value of dioleoyl phosphatidylethanolemine in which case the the HLB requirement amount of a secondary surfactant is 0. By appropriate selection of dioleoyl phosphatidylethanolamine to secondary surfactant ratios, it is possible to prepare emulsions for pharmaceutical delivery of a bioactive agent using an oil phase having a required HLB value up to about 17.4. Above a required HLB value of about 17.4. dioleoyl phosphatidylethanolamine may be used to reduce the amount of secondary surfactant required to form an emulsion.
摘要翻译：公开了一种用于递送生物活性剂的新型油和水乳液。该乳液包含第一HLB要求量的表面活性剂二油酰磷脂酰乙醇胺。在具体实施方案中，乳液包括除二油酰磷脂酰乙醇胺以外的第二表面活性剂，除了在HLB要求是二油酰磷脂酰乙醇胺的HLB值的情况下，在这种情况下，第二表面活性剂的HLB需求量为0.通过适当选择二油酰磷脂酰乙醇胺对于次级表面活性剂比例，可以制备用于药物递送生物活性剂的乳液，其使用具有高达约17.4的所需HLB值的油相。高于所需HLB值约17.4。二油酰基磷脂酰乙醇胺可用于减少形成乳液所需的第二表面活性剂的量。

15. 发明授权

US5395618A Ocular insert with anchoring protrusions 失效
标题翻译：眼插入物与锚定突起
公开(公告)号：US5395618A
公开(公告)日：1995-03-07
申请号：US243915
申请日：1994-05-17
申请人： Sohrab Darougar , Alan L. Weiner
发明人： Sohrab Darougar , Alan L. Weiner
IPC分类号： A61F9/007 , A61F9/00 , A61K9/00 , B82B1/00
CPC分类号： A61F9/0017 , A61K9/0051
摘要： A flexible ocular insert device adapted for the controlled sustained release of an ophthalmic drug into the eye. In one embodiment, the device includes an elongated body of a polymeric material in the form of a rod or tube containing a pharmaceutically active ingredient and with at least two anchoring protrusions extending radially outwardly from the body. The device has a length of at least 8 mm and the diameter of its body portion including the protrusions does not exceed 1.9 mm. The sustained release mechanism may, for example, be by diffusion or by osmosis or bioerosion. The insert device is advantageously inserted into the upper or lower fornix of the eye so as to be independent of movement of the eye by virtue of the fornix anatomy. The protrusions may be of various shapes such as, for example, ribs, screw threads, dimples or bumps, truncated cone-shaped segments or winding braid segments. In a further embodiment, the polymeric material for the body is selected as one which swells in a liquid environment. Thus a device of smaller initial size may be employed. The present insert device is of a size and configuration such that, upon insertion into the upper or lower fornix, the device remains out of the field of vision so as to be well retained in place and imperceptible by a patient over a prolonged period of use. The device can be retained in the upper or lower fornix for 7 to 14 days or longer.
摘要翻译：一种柔性眼部插入装置，适于将眼药物的受控持续释放到眼睛中。在一个实施方案中，该装置包括呈杆状或管状形式的聚合物材料的细长体，其包含药物活性成分，并且具有至少两个从身体径向向外延伸的锚定突起。该装置具有至少8mm的长度，并且其主体部分包括突起的直径不超过1.9mm。持续释放机制可以例如通过扩散或渗透或生物侵蚀。插入装置有利地插入眼睛的上部或下部穹窿中，以便凭借穹窿解剖结构独立于眼睛的移动。突起可以是各种形状，例如肋，螺纹，凹坑或凸起，截头圆锥形段或缠绕编织段。在另一个实施方案中，用于身体的聚合物材料选择为在液体环境中溶胀的聚合物材料。因此，可以采用较小初始尺寸的装置。本插入装置的尺寸和构造使得在插入上部或下部穹窿中时，该装置保持离开视野，以便能够在长时间使用时良好地保持在适当位置并且被患者察觉不到。该装置可以保留在上，下穹顶7至14天或更长时间。

16. 发明授权

US5330689A Entrapment of water-insoluble compound in alpha tocopherol-based vesicles 失效
标题翻译：在基于α-生育酚的囊泡中封闭水不溶性化合物
公开(公告)号：US5330689A
公开(公告)日：1994-07-19
申请号：US39941
申请日：1993-03-29
申请人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini , Robert L. Suddith
发明人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini , Robert L. Suddith
IPC分类号： A61K9/127 , A61K9/133 , A61K31/355
CPC分类号： A61K9/1272 , A61K31/355 , A61K9/1277 , Y10S436/829 , Y10S514/885 , Y10S514/913 , Y10T428/2984
摘要： Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and efficient and does not require the use of organic solvents. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.
摘要翻译：描述了用于制备α-生育酚囊泡的方法和组合物，其双层包含α-生育酚的有机酸衍生物的盐形式，例如α-生育酚半琥珀酸盐的三盐盐形式。该方法快速有效，不需要使用有机溶剂。 α-生育酚囊泡可用于捕获不溶于水溶液的化合物。这种制剂对于捕获有限溶解度的生物活性剂特别有用，因此能够在体内施用。

17. 发明授权

US5234634A Method for preparing alpha-tocopherol vesicles 失效
标题翻译：制备ALPHA-TOCOPHEROL VESICLES的方法
公开(公告)号：US5234634A
公开(公告)日：1993-08-10
申请号：US599290
申请日：1990-10-17
申请人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini
发明人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini
IPC分类号： A61K9/127 , A61K9/133 , A61K31/355
CPC分类号： A61K9/1272 , A61K31/355 , A61K9/1277 , Y10S436/829 , Y10S514/885 , Y10S514/913 , Y10T428/2984
摘要： Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and efficient and does not require the use of organic solvents. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.

18. 发明授权

US5041278A Alpha tocopherol-based vesicles 失效
标题翻译：基于α-生育酚的囊泡
公开(公告)号：US5041278A
公开(公告)日：1991-08-20
申请号：US280551
申请日：1988-12-06
申请人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini
发明人： Andrew S. Janoff , Lois E. Bolcsak , Alan L. Weiner , Paul A. Tremblay , Michael V. W. Bergamini
IPC分类号： A61K9/127 , A61K9/133 , A61K31/355
CPC分类号： A61K9/1272 , A61K31/355 , A61K9/1277 , Y10S436/829 , Y10S514/885 , Y10S514/913 , Y10T428/2984
摘要： Methods and compositions are described for the preparation of alpha-tocopherol vesicles, the bilayers of which comprise a salt form of an organic acid derivative of alpha-tocopherol such as the Tris salt form of alpha-tocopherol hemisuccinate. The method is rapid and efficient and does not require the use of organic solvents. The alpha-tocopherol vesicles may be used to entrap compounds which are insoluble in aqueous solutions. Such preparations are especially useful for entrapping bioactive agents of limited solubility, thus enabling administration in vivo.
摘要翻译：描述了用于制备α-生育酚囊泡的方法和组合物，其双层包含α-生育酚的有机酸衍生物的盐形式，例如α-生育酚半琥珀酸盐的三盐盐形式。该方法快速有效，不需要使用有机溶剂。 α-生育酚囊泡可用于捕获不溶于水溶液的化合物。这种制剂对于捕获有限溶解度的生物活性剂特别有用，因此能够在体内施用。

19. 发明申请

US20100174272A1 IN-SITU REFILLABLE OPHTHALMIC IMPLANT 审中-公开
公开(公告)号：US20100174272A1
公开(公告)日：2010-07-08
申请号：US12641352
申请日：2009-12-18
申请人： Alan L. Weiner
发明人： Alan L. Weiner
IPC分类号： A61F9/00 , A61M37/00
CPC分类号： A61F9/0017
摘要： The present invention is directed to an in-situ refillable ophthalmic implant having a refill port in communication with a reservoir and a release control mechanism. The present invention also relates to methods of forming and using the ophthalmic implant. Preferably, the control release mechanism include opening[s] providing for passive passage of pharmaceutical ophthalmic composition, particularly therapeutic agent, out of the reservoir, through the opening[s] and into the eye.
摘要翻译：本发明涉及一种具有与储存器连通的再填充口和释放控制机构的原位可再充注眼科植入物。本发明还涉及形成和使用眼科植入物的方法。优选地，控制释放机构包括提供药物眼用组合物，特别是治疗剂被动地通过储存器通过开口并进入眼睛的开口。

20. 发明授权

US5989579A Ocular insert with anchoring protrusions 失效
公开(公告)号：US5989579A
公开(公告)日：1999-11-23
申请号：US934382
申请日：1997-09-19
申请人： Sohrab Darougar , Alan L. Weiner , Padmanabh Pravinchandra Bhatt , Victor Albert Raul , David Clayton Gantner
发明人： Sohrab Darougar , Alan L. Weiner , Padmanabh Pravinchandra Bhatt , Victor Albert Raul , David Clayton Gantner
IPC分类号： A61F9/00 , A61K9/00
CPC分类号： A61F9/0017 , A61K9/0051
摘要： A flexible ocular insert device adapted for the controlled sustained release of an ophthalmic drug into the eye. In one embodiment, the device includes an elongated body of a polymeric material in the form of a rod or tube containing a pharmaceutically active ingredient and with at least two anchoring protrusions extending radially outwardly from the body. The device has a length of at least 8 mm and the diameter of its body portion including the protrusions does not exceed 1.9 mm. The sustained release mechanism may, for example, be by diffusion or by osmosis or bioerosion. The insert device is advantageously inserted into the upper or lower fornix of the eye so as to be independent of movement of the eye by virtue of the fornix anatomy. The protrusions may be of various shapes such as, for example, ribs, screw threads, dimples or bumps, truncated cone-shaped segments or winding braid segments. In a further embodiment, the polymeric material for the body is selected as one which swells in a liquid environment. Thus a device of smaller initial size may be employed. The present insert device is of a size and configuration such that, upon insertion into the upper or lower fornix, the device remains out of the field of vision so as to be well retained in place and imperceptible by a patient over a prolonged period of use. The device can be retained in the upper or lower fornix for 7 to 14 days or longer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式